항체 단편 시장 규모, 점유율, 성장 분석 : 특이성별, 단편 유형별, 용도별, 최종 용도별, 지역별 - 업계 예측(2025-2032년)

Global Antibody Fragments Market size was valued at USD 7.2 billion in 2023 and is poised to grow from USD 7.62 billion in 2024 to USD 11.96 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The antibody fragments market is emerging as a vital segment within the broader biological arena, fueled by the rising need for targeted and efficient therapeutics and diagnostics. With various formats such as Fab fragments, single-chain variable fragments (scFv), and nanobodies, these fragments offer substantial benefits over traditional monoclonal antibodies. Advances in protein engineering, display technologies, and computational design are enhancing the stability, binding, and manufacturability of these fragments. As demand for innovative therapeutic options grows, antibody fragments are increasingly recognized as foundational elements for bispecifics, antibody-drug conjugates (ADCs), and CAR constructs, particularly in oncology and rare diseases. Their rapid clearance and specificity also make them suitable for diagnostics, imaging, and personalized medicine, further driving market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Fragments market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Fragments Market Segments Analysis

Global Antibody Fragments Market is segmented by Specificity, Fragment Type, Application, End Use and region. Based on Specificity, the market is segmented into Monoclonal Antibody Fragments and Polyclonal Antibody Fragments. Based on Fragment Type, the market is segmented into Fab Fragments, scFv (Single-Chain Variable Fragments), sdAb (Single-Domain Antibodies / Nanobodies) and Others. Based on Application, the market is segmented into Therapeutics, Diagnostics and Research Tools & Kits. Based on End Use, the market is segmented into Oncology, Immunology / Autoimmune Diseases, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Fragments Market

One key market driver for the global antibody fragments market is the increasing demand for targeted therapies in the treatment of various diseases, including cancer and autoimmune disorders. As the understanding of cancer biology advances, the desire for more precise and effective treatments has led to a surge in interest in antibody fragments, such as single-chain variable fragments (scFvs) and bispecific antibodies. These fragments offer advantages like smaller size, enhanced tissue penetration, and reduced immunogenicity compared to full-length antibodies. Furthermore, their versatility in drug development and potential for combination therapies contribute significantly to the expanding market landscape.

Restraints in the Global Antibody Fragments Market

One of the key market restraints for the global antibody fragments market is the high cost associated with the research and development of these specialized therapeutics. The complexity of antibody engineering and the stringent regulatory requirements for clinical trials necessitate significant financial investment, which can limit the entry of smaller biotech firms and restrict innovation. Additionally, the competitive landscape, featuring established pharmaceutical companies with robust pipelines, poses challenges for new entrants seeking market share. These factors can impede growth and reduce the overall accessibility of antibody fragment-based therapies, hindering advancements in targeted treatment options.

Market Trends of the Global Antibody Fragments Market

The Global Antibody Fragments market is experiencing significant growth, particularly within the oncology and diagnostics sectors. This trend is fueled by the rising adoption of antibody fragments, which offer superior tumor penetration and rapid circulation clearance, making them ideal for both imaging agents and targeted therapies when radiolabeled. The focus on fragment-based conjugates and bispecific antibodies is intensifying, as researchers and developers aim to enhance therapeutic efficacy while minimizing off-target effects through modularity. This innovative approach not only enhances the precision of cancer treatments but also prompts further exploration of antibody fragments in various therapeutic and diagnostic applications, driving market expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Antibody Fragments Market Size by Specificity & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibody Fragments
• Polyclonal Antibody Fragments

Global Antibody Fragments Market Size by Fragment Type & CAGR (2025-2032)

• Market Overview
• Fab Fragments
• scFv (Single-Chain Variable Fragments)
• sdAb (Single-Domain Antibodies / Nanobodies)
• Others

Global Antibody Fragments Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Diagnostics
• Research Tools & Kits

Global Antibody Fragments Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Oncology
• Immunology / Autoimmune Diseases
• Infectious Diseases
• Others

Global Antibody Fragments Market Size & CAGR (2025-2032)

• North America (Specificity, Fragment Type, Application, End Use)
  • US
  • Canada
• Europe (Specificity, Fragment Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specificity, Fragment Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specificity, Fragment Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specificity, Fragment Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ablynx (Sanofi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harpoon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Huasun Technology Group Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations